Lawrence Fong, MD
Enriched profilePhysician; Scientific Director, Immunotherapy Integrated Research Center; Professor, Translational Science and Therapeutics, Fred Hutch Cancer Center; Professor of Medicine, Division of Hematology and Oncology, University of Washington · Fred Hutchinson Cancer Center
Lawrence Fong is Physician; Scientific Director, Immunotherapy Integrated Research Center; Professor, Translational Science and Therapeutics, Fred Hutch Cancer Center; Professor of Medicine, Division of Hematology and Oncology, University of Washington at Fred Hutchinson Cancer Center. OpenAlex indexes 770 publications with 35,279 citations (h-index 75); ClinicalTrials.gov lists 9 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Lawrence Fong, MD, is Physician at Fred Hutchinson Cancer Center. The public record shows 770 publications with 35,279 citations (h-index 75), centered on Cancer Immunotherapy and Biomarkers, Prostate Cancer Treatment and Research, Immunotherapy and Immune Responses. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 18 companies, 1 NIH-funded awards (2024–2026).
- Most recent indexed publication: 2026 · Nature cancer
- Top research focus: Cancer Immunotherapy and Biomarkers
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 18 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 32 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 216.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
Sponsor: MedPacto, Inc.
- Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
Sponsor: Lawrence Fong
Industry payments
Updated 14 Oct 2026
18 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202512 payments$20,636openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim RCV GmbH & Co KGProgram year20251 payment
- ROCHE MOLECULAR SYSTEMS, INC.Program year20257 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
71.4%Cytochrome P450 17A1 Inhibitor42.9%Abiraterone Acetate100%Part D<11 patientsGonadotropin Releasing Hormone Receptor Antagonist28.6%Orgovyx100%Part D<11 patientsMetabolism & gastrointestinal
28.6%Corticosteroid28.6%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
- Determinants of response to cancer immunotherapy
Fred Hutchinson Cancer Center
FY2026$1,055,426R35CA253175 - Project 1-Combination Immunotherapy with Radioligned Therapy for Metastatic Prostate Cancer
University of California, San Francisco
FY2026$451,950P50CA275741 - Determinants of response to cancer immunotherapy
Fred Hutchinson Cancer Center
FY2025$1,055,838R35CA253175
Congress activity
Updated 14 Oct 2026
147 congress contributions (2006–2026) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
- Abstract 4325: FXYD5 plays diverse roles in immune evasion and tumor progression in prostate cancer
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Functionally heterogeneous intratumoral CD4(+)CD8(+) double-positive T cells can give rise to single-positive T cells.
Proceedings of the National Academy of Sciences of the United States of America
Article2026 - Tumor cell heterogeneity drives spatial organization of the intratumoral immune response.
The Journal of experimental medicine
Article2025
Most-cited works
by citation count (OpenAlex)- 01TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cellsArticle5,562 citations2018
- 02Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaArticle3,410 citations2017
- 03Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and MemoryArticle1,343 citations2019
- 04
- 05Characterization of circulating T cells specific for tumor-associated antigens in melanoma patientsArticle1,121 citations1999
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/lawrence-fong-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Editorial & leadership roles
journal and society appointments- Scientific Director
Immunotherapy Integrated Research Center, Fred Hutch Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗ - Elected Member
Board of Directors, Society for Immunotherapy of Cancer (SITC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗ - Inaugural Senior Editor
Cancer Immunology Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗ - Inaugural Senior Editor
Journal for ImmunoTherapy of Cancer (JITC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
- National Cancer Institute Outstanding Investigator Award
2021 ($4.2 million over 7 years, "Determinants of Response to Cancer Immunotherapy")
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine
Division of Hematology and Oncology, University of Washington School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hemonc.uw.edu ↗
Media & interviews
press, podcasts and appearances- "Dr. Lawrence Fong, new Fred Hutch immunotherapy director, talks about how the field has transformed oncology"
Fred Hutch News feature/Q&A, August 2024
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗ - "Dr. Lawrence Fong to lead Immunotherapy Integrated Research Center"
Fred Hutch News feature, October 2023
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healio.com ↗
- "Faculty spotlight: Lawrence Fong"
UW Department of Medicine News
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mednews.uw.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
David Maloney, MD, PhD
Fred Hutchinson Cancer Center
Brenda Sandmaier, MD
Fred Hutchinson Cancer Center
Alpana Waghmare, MD
Fred Hutchinson Cancer Center
Michael Boeckh, MD
Fred Hutchinson Cancer Center
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)